We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win
Read MoreHide Full Article
Intelligent Bio Solutions Inc. (INBS - Free Report) recently announced that it has secured a key patent in the United States relating to the Intelligent Fingerprinting Drug Screening Cartridge. This is the company’s sixth active patent to be granted in the United States, strengthening the protection of its unique and proprietary drug screening technology.
With this strategic milestone, INBS aims to enhance its competitive edge in the industry while accelerating the commercialization of the technology. As the company moves closer to market launch, the strengthened intellectual property (“IP”) protection underscores confidence in its product's potential impact.
Likely Trend of INBS Stock Following the News
Following the announcement, shares of the company tumbled 5.1% and closed at $1.67 yesterday. In the past six months, INBS’ shares have lost 8.2% compared with the industry’s 13.2% decline. The S&P 500 improved 1% in the same time frame.
However, securing a key U.S. patent strengthens INBS’ competitive edge by protecting its proprietary technology, reducing the risk of imitation and reinforcing investor confidence in long-term growth potential. This milestone enhances the company’s positioning ahead of its 2025 drug screening market entry, increasing the likelihood of successful commercialization and potential partnerships. As demand for innovative biometric diagnostic solutions rises, a strong IP portfolio can attract institutional investors, improve market perception and drive sustainable revenue growth, ultimately boosting the performance of the INBS stock over time.
Meanwhile, INBS currently has a market capitalization of $11.9 billion. The company expects an earnings growth of 80.4% in 2025.
Image Source: Zacks Investment Research
More on INBS’ Intelligent Fingerprinting Drug Screening Cartridge
INBS has developed a robust IP portfolio to safeguard its innovative drug screening technology. The company has been granted six active U.S. patents, each covering distinct aspects of its Intelligent Fingerprinting Drug Screening System. These patents encompass the proprietary lateral flow test strip within the Drug Screening Cartridge, the Sample Collection Cartridge, the cartridge housing and the buffer clip design. This comprehensive IP protection reinforces INBS' competitive position as it prepares to enter the U.S. drug screening market in 2025.
INBS’ Intelligent Fingerprinting Drug Screening Cartridge is a cutting-edge, non-invasive drug testing solution, designed to detect drug metabolites through fingerprint sweat analysis. Unlike traditional urine or blood tests, this innovative approach offers rapid, hygienic and user-friendly screening, making it ideal for workplace testing, law enforcement, rehabilitation programs and clinical applications.
The cartridge works by collecting a small sweat sample from a fingerprint, which is then analyzed using INBS’ portable reader, delivering results in minutes. This method eliminates the need for invasive sample collection, reducing the risk of contamination, tampering or privacy concerns often associated with conventional drug testing. Additionally, the compact and portable design enhances accessibility, allowing for on-the-spot testing in various environments.
Favorable Industry Prospects for INBS
Per a report by Marketsandmarkets, the global drug screening market was valued at $7.7 billion in 2023 and is forecasted to grow at a robust CAGR of 16.6%, reaching an impressive $19.5 billion by 2029. INBS is poised to tap into the $19.5 billion drug screening market with its patented, non-invasive and rapid fingerprint drug test.
Masimo’s shares have rallied 30.1% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have gained 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win
Intelligent Bio Solutions Inc. (INBS - Free Report) recently announced that it has secured a key patent in the United States relating to the Intelligent Fingerprinting Drug Screening Cartridge. This is the company’s sixth active patent to be granted in the United States, strengthening the protection of its unique and proprietary drug screening technology.
With this strategic milestone, INBS aims to enhance its competitive edge in the industry while accelerating the commercialization of the technology. As the company moves closer to market launch, the strengthened intellectual property (“IP”) protection underscores confidence in its product's potential impact.
Likely Trend of INBS Stock Following the News
Following the announcement, shares of the company tumbled 5.1% and closed at $1.67 yesterday. In the past six months, INBS’ shares have lost 8.2% compared with the industry’s 13.2% decline. The S&P 500 improved 1% in the same time frame.
However, securing a key U.S. patent strengthens INBS’ competitive edge by protecting its proprietary technology, reducing the risk of imitation and reinforcing investor confidence in long-term growth potential. This milestone enhances the company’s positioning ahead of its 2025 drug screening market entry, increasing the likelihood of successful commercialization and potential partnerships. As demand for innovative biometric diagnostic solutions rises, a strong IP portfolio can attract institutional investors, improve market perception and drive sustainable revenue growth, ultimately boosting the performance of the INBS stock over time.
Meanwhile, INBS currently has a market capitalization of $11.9 billion. The company expects an earnings growth of 80.4% in 2025.
Image Source: Zacks Investment Research
More on INBS’ Intelligent Fingerprinting Drug Screening Cartridge
INBS has developed a robust IP portfolio to safeguard its innovative drug screening technology. The company has been granted six active U.S. patents, each covering distinct aspects of its Intelligent Fingerprinting Drug Screening System. These patents encompass the proprietary lateral flow test strip within the Drug Screening Cartridge, the Sample Collection Cartridge, the cartridge housing and the buffer clip design. This comprehensive IP protection reinforces INBS' competitive position as it prepares to enter the U.S. drug screening market in 2025.
INBS’ Intelligent Fingerprinting Drug Screening Cartridge is a cutting-edge, non-invasive drug testing solution, designed to detect drug metabolites through fingerprint sweat analysis. Unlike traditional urine or blood tests, this innovative approach offers rapid, hygienic and user-friendly screening, making it ideal for workplace testing, law enforcement, rehabilitation programs and clinical applications.
The cartridge works by collecting a small sweat sample from a fingerprint, which is then analyzed using INBS’ portable reader, delivering results in minutes. This method eliminates the need for invasive sample collection, reducing the risk of contamination, tampering or privacy concerns often associated with conventional drug testing. Additionally, the compact and portable design enhances accessibility, allowing for on-the-spot testing in various environments.
Favorable Industry Prospects for INBS
Per a report by Marketsandmarkets, the global drug screening market was valued at $7.7 billion in 2023 and is forecasted to grow at a robust CAGR of 16.6%, reaching an impressive $19.5 billion by 2029. INBS is poised to tap into the $19.5 billion drug screening market with its patented, non-invasive and rapid fingerprint drug test.
INBS’ Zacks Rank & Stocks to Consider
INBS carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) . At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have rallied 30.1% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have gained 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.